Slow acetylation activity and its associated NAT2 genotype are generally associated with increased risk for bladder cancer in general populations and in workers exposed to arylamine mixtures. For workers exposed to benzidine, a borderline protective association has been reported. The purpose of this study was to evaluate the impact that metabolic polymorph isms have on bladder cancer in Chinese workers exposed only to benzidine. This nested case-control study included 30 cases with transitional cell carcinoma of the urinary bladder, diagnosed after 1991. Sixty seven controls, frequency-matched by decade of birth, were selected. NAT2 and CYP 1 A2 enzymatic activities were characterized by measuring urinary caffeine metabolite ratios as phenotypic function markers. Polymerase chain reaction-based methods were used to identify genotypes for the following genes: NAT2, NAT1, GSTM1, GSTT1, GSTP1, and UGTIA1. Crude analysis of bladder cancer risk shows an odds ratio of 0.1 (95% confidence interval: 0.01 - 0.92) for workers with the NAT2 slow genotype. Adjustment for lifetime smoking, age, and NATI genotype did not alter the findings. A protective but not significant association was found for slow acetylation phenotype. NATl, GSTMl, and GSTTI polymorphisms showed no association with bladder cancer risk; frequencies of the rare alleles for GSTP 1 and UGT1A1 were too low for analysis. These findings suggest that the risk of bladder cancer from benzidine exposure is due to activation by N-acetylation.
Links with this icon indicate that you are leaving the CDC website.
The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
You will be subject to the destination website's privacy policy when you follow the link.
CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.
For more information on CDC's web notification policies, see Website Disclaimers.
CDC.gov Privacy Settings
We take your privacy seriously. You can review and change the way we collect information below.
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Cookies used to make website functionality more relevant to you. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests.
Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data.
Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. These cookies may also be used for advertising purposes by these third parties.
Thank you for taking the time to confirm your preferences. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page.